These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12820313)

  • 21. Evaluation of the Performance of a Fecal Tumor M2-PK Rapid Kit Using Stool Specimens for Detection of Colorectal Tumors.
    Cho CH; Kim J; Jang MA; Lee BJ; Park JJ; Lim CS
    Ann Clin Lab Sci; 2016; 46(2):154-60. PubMed ID: 27098621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen.
    Kim Y; Lee S; Park S; Jeon H; Lee W; Kim JK; Cho M; Kim M; Lim J; Kang CS; Han K
    Ann Clin Lab Sci; 2003; 33(1):32-8. PubMed ID: 12661896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
    Lüftner D; Mesterharm J; Akrivakis C; Geppert R; Petrides PE; Wernecke KD; Possinger K
    Anticancer Res; 2000; 20(6D):5077-82. PubMed ID: 11326672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.
    Schulze G
    Anticancer Res; 2000; 20(6D):4961-4. PubMed ID: 11326647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM; Teigelkamp S; Kramer W; Eigenbrodt E; Usadel KH
    Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative detection of tumor M2-PK in serum and plasma.
    Hugo F; Fischer G; Eigenbrodt E
    Anticancer Res; 1999; 19(4A):2753-7. PubMed ID: 10470235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stool test for colorectal cancer screening--it's time to move!
    Loitsch SM; Shastri Y; Stein J
    Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
    Schneider J; Morr H; Velcovsky HG; Weisse G; Eigenbrodt E
    Cancer Detect Prev; 2000; 24(6):531-5. PubMed ID: 11198266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas.
    Shastri YM; Stein JM
    Br J Cancer; 2008 Oct; 99(8):1366; author reply 1367. PubMed ID: 18827821
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
    Kaura B; Bagga R; Patel FD
    J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
    Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
    Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders.
    Jeffery J; Lewis SJ; Ayling RM
    Inflamm Bowel Dis; 2009 Nov; 15(11):1630-4. PubMed ID: 19462434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
    Oremek GM; Gerstmeier F; Sauer-Eppel H; Sapoutzis N; Wechsel HW
    Anticancer Res; 2003; 23(2A):1127-30. PubMed ID: 12820359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
    Goonetilleke KS; Mason JM; Siriwardana P; King NK; France MW; Siriwardena AK
    Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
    Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer.
    Mizuno M; Mizuno M; Iwagaki N; Nasu J; Okazaki H; Yamamoto K; Okada H; Tsuji T; Fujita T; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2550-5. PubMed ID: 14638362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fecal lysozyme: an unreliable marker for colorectal cancer.
    Dubrow R; Kim CS; Eldred AK
    Am J Gastroenterol; 1992 May; 87(5):617-21. PubMed ID: 1595650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid fecal cytokeratin-19 test and fecal occult blood test in screening for gastrointestinal diseases.
    Kim H; Kim Y; Yoon S; Lim J; Kim M; Lee S; Kang S; Lee EJ; Kang CS; Han K
    Ann Clin Lab Sci; 2006; 36(3):294-8. PubMed ID: 16951270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening.
    Takai T; Kanaoka S; Yoshida K; Hamaya Y; Ikuma M; Miura N; Sugimura H; Kajimura M; Hishida A
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1888-93. PubMed ID: 19505922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
    Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
    Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.